REG - GSK PLC - Statement: Zantac (ranitidine) litigation

GSKAnnouncement

16/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240816:nRSP6775Aa&default-theme=true

RNS Number : 6775A  GSK PLC  16 August 2024

Issued: 15 August 2024, London UK

 

Statement: Zantac (ranitidine) litigation - Florida State Court Daubert Ruling
in Wilson case

 

·      Florida State Court's ruling finds in favour of GSK and other
defendants, excluding plaintiff's experts' general and specific causation
testimony that ranitidine was a significant risk factor for Wilson's prostate
cancer

·     Court's ruling is consistent with scientific consensus that there is
no consistent or reliable evidence that ranitidine increases the risk of any
cancer

·     GSK continues to vigorously defend itself, including against all
claims in other jurisdictions

 

 

GSK plc (LSE/NYSE: GSK) welcomes today's Daubert ruling by the Florida State
Court. In excluding plaintiffs' expert testimony as unreliable, GSK will now
seek dismissal of the upcoming Wilson case in Florida - whereby plaintiffs
alleged a causal link between ranitidine and prostate cancer.

 

Today's decision echoes the December 2022 ruling by Judge Rosenberg in the
federal multidistrict litigation (MDL), which rejected all expert evidence put
forward by the plaintiffs and dismissed all MDL cases alleging bladder,
esophageal, gastric, liver, or pancreatic cancer. Both the MDL and Florida
courts have determined that the methodology used by plaintiffs' experts is
unreliable and fails to meet the Daubert standard for scientific evidence.

 

Since 2019, following the 16 epidemiological studies looking at human data
regarding the use of ranitidine, the scientific consensus is that there is no
consistent or reliable evidence that ranitidine increases the risk of any
cancer. Today's ruling reflects the state of that science and ensures that
unreliable and litigation-driven science does not enter the courtroom.

 

GSK continues to defend itself vigorously, including against all remaining
claims in other jurisdictions.

 

Notes to Editors

* The Daubert standard, established in the U.S. Supreme Court case Daubert v.
Merrell Dow Pharmaceuticals, Inc. 509 US 579 (1993) provides criteria for
evaluating whether expert testimony is admissible under Federal Rule of
Evidence 702.  Under Rule 702 and Daubert, an expert may offer testimony if
he or she is qualified by knowledge, education, training or experience in a
given area and the testimony offered is reliable, relevant and helpful to the
jury.  In applying the Daubert standard, the Court acts as a gatekeeper,
ensuring that expert opinions meet certain standards for reliability and that
speculative or unreliable opinions are not presented to the jury.   In
Daubert, the Supreme Court identified four factors to guide assessment of an
expert's methodology: (1) whether the expert's methodology has been tested or
is capable of being tested; (2) whether the theory or technique used by the
expert has been subjected to peer review and publication; (3) whether there is
a known or potential error rate of the methodology; and (4) whether the
technique has been generally accepted in the relevant scientific community.
The Daubert standard is applicable to expert testimony in all federal cases.
Many states also have adopted standards identical to the federal Daubert
standard.

 

The term "Daubert Standard" comes from the United States Supreme Court case:
Daubert v Merrell Dow Pharmaceuticals Inc 509 US 579 (1993).

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Dan Smith          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q2 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRGPUAARUPCPGA